G2’s Molecular Diagnostics Conference has assembled a world-class faculty of molecular experts and laboratory business leaders from some of the nation’s top molecular labs in the areas of molecular business strategy, reimbursement, billing, legal, regulations, and results reporting.
Gyorgy Abel, M.D., Ph.D.,
Medical Director, Clinical Chemistry and Molecular Diagnostics/Clinical Immunology, Department of Laboratory Medicine, Lahey Clinic
Gyorgy Abel is the Medical Director of Clinical Chemistry and Molecular Diagnostics/Clinical Immunology at Lahey Clinic Medical Center. He received his M.D. degree at the Medical School of Debrecen, Hungary. He moved to the United States in 1988 and worked as a post-doctoral fellow in the Brigham and Women’s Hospital, Harvard Medical School, where he gained expertise in molecular biology. Dr. Abel completed a pathology residency at the Massachusetts General Hospital in 2000, and became board certified in Clinical Pathology (ABP), and in Molecular Diagnostics (ABCC). He is a fellow of the College of American Pathologists, the National Academy of Clinical Biochemistry and the Royal Society of Medicine (UK).
His areas of clinical and research interests encompass molecular diagnostics, clinical immunology, clinical chemistry, and personalized medicine, with special focus on minimal residual detection with molecular methods in cancer. He is a frequent speaker on topics in molecular diagnostics at national and international conferences.
Franklin Cockerill, M.D.,
Chair, Laboratory Medicine and Pathology, Mayo Clinic
Frank Cockerill is the Chair of Department of Laboratory Medicine and Pathology, Mayo Clinic, and President and CEO of Mayo Collaborative Services, Inc. (MCSI)/Mayo Medical Laboratories (MML). He also carries a named professorship, the Ann and Leo Markin Professor of Medicine and Microbiology at the Mayo Medical School. Dr. Cockerill is Board Certified in Internal Medicine and Infectious Diseases (American Board of Internal Medicine) and Clinical Microbiology (American Board of Pathology). He practiced Internal Medicine and Infectious Diseases for over a decade before shifting his focus to Clinical Microbiology. His research interests have ranged from basic discovery to applied science with a special emphasis on the phenotypic and genotypic identification of antimicrobial resistance.
Dr. Cockerill has authored or co-authored over 150 publications in the medical literature many of which relate to diagnostic testing for infectious diseases. He and his research team at Mayo have developed numerous real-time PCR assays, which have significant advantages over conventional culture-based assays, and include the first commercially available rapid PCR test for Anthrax. This work has resulted in 8 US patents, 2 foreign patents and 56 licensed technologies.
As President and CEO of MCSI, Dr. Cockerill oversees the largest for-profit company associated with Mayo Clinic. The major service line of MCSI, MML, is the third largest provider of esoteric laboratory services in the United States and in total serves over 4,000 clients in 130 countries. In addition to his Mayo administrative assignments, Dr. Cockerill currently holds several high profile extramural leadership positions, including Immediate Past Chair of the Subcommittee on Antimicrobial Susceptibility Testing, Clinical Laboratory Standards Institute; Chair, Microbiology Devices Panel of the Medical Devices Advisory Committee of the U.S. Food and Drug Administration; Chair, Program Committee of the Association for Molecular Pathology; Member, Board of Scientific Counselors of the Centers for Disease Control and Prevention; and Member, Board of Directors, American Clinical Laboratory Association.
Dr. Cockerill has received numerous awards, fellowships and honors, including the American Society for Microbiology-sponsored BD Award for Research in Clinical Microbiology, the G2 Intelligence Laboratory Public Service National Leadership Award, and Fellowship in the American Academy of Microbiology.
Vice President Reimbursement and Payer Strategy, Foundation Medicine, Inc.
Jerry Conway, Vice President of Reimbursement & Payer Strategy, joined Foundation Medicine Inc. in May 2012 with over 22 years of sales and executive management experience in the routine clinical and esoteric laboratory marketplaces working first in physician sales and marketing, then later with national and regional payers on contracting, education and utilization management initiatives involving laboratory services. His experience includes payer contracting and reimbursement in a wide range of business environments including Fortune 500 and start-up companies. In 2011, Jerry joined Metamark Genetics Inc., a national provider of cancer prognostic tests and services, as Vice President of Reimbursement & Payer Contracting. At Metamark, Jerry was responsible for payer strategy development for several assays in the pre-launch phase.
In 1997, Jerry joined Genzyme Genetics, a national provider of genetic health services, to develop business relationships and contracts with regional and national payers based in the Northeastern United States. In 2001, he was promoted to the role of Director of National Accounts with Genzyme Genetics and was responsible for business development and contracts with national and cross-regional payers. In 2004, Jerry was promoted to Vice President of Managed Care where he oversaw a staff of 11 regional and national account directors who were focused on payer account management, contracting, pull through, education and care management programming. With a particular focus on reimbursement for routine and novel genetic tests and services in the reproductive and oncology markets at Genzyme Genetics, Jerry has a demonstrated track record of increased revenue and profitability. Under his leadership in payer contracting and reimbursement over 14 years, Jerry helped to favorably position the company for a recent $975 million acquisition by Laboratory Corporation of America® Holdings on December 1, 2010.
Managing Partner, BioScience Biz
Beverly Cormier has more than twenty years of experience spanning the genomic, clinical diagnostics, and medical device industries. Prior to founding BioScience Biz, where she is Managing Partner, Ms. Cormier was Vice President, Commercialization of Exagen Diagnostics, a specialty clinical laboratory services business focused on gastroenterology and rheumatology products. She began her career in sales at Dianon Systems, then moved to UroCor, where she was national sales manager. She was then recruited to Prometheus as director of sales, marketing, and business development, playing a key role in setting up and executing the company’s commercial operations.
She graduated cum laude from the University of Cincinnati with a BS degree in Health Sciences and did graduate work in health care at Miami University. Ms. Cormier has written A Guide to Raising Capital from the Private Sector (Drug and Market Research Publications), served as a national speaker for IBC Life Sciences and the Forum for Women’s Entrepreneurs, and participated as a mentor for the Rady School of Management MBA program. She is also a member of TechCoast Angels.
Glenda Flemister M.D., FACP, FCCP
Medical Director, Aetna
Glenda Flemister received her doctorate of Medicine from Loyola Stritch School of Medicine, and completed a residency in internal medicine at Michael Reese Hospital and Medical Center in Chicago. Fellowship training followed at Hines-Loyola Medical Center in pulmonary medicine and critical care medicine. Dr. Flemister is board certified in internal medicine, pulmonary medicine, and critical care medicine. She is a fellow of the American College of Physicians, and a fellow of the American College of Chest Physicians. She is also a member of the American College of Physician Executives, Society of Critical Care Medicine, and American Thoracic Society.
Dr. Flemister currently works as a medical director at Aetna, and is actively involved in Aetna’s Clinical Policy Bulletin development, Subspecialty Medicine Committee, and Comparative Research Analysis Team. She also provides educational lectures both internally and externally and provides support to the staff. Prior to that, she was in private practice, and performed consulting services in a variety of areas, including pulmonary rehabilitation, critical care medicine, and pulmonary medicine.
Patric Hooper Esq,
Partner, Hooper Lundy & Bookman and counsel to the California Clinical Laboratory Association
Patric Hooper received his A.B. degree in economics from the University of California at Los Angeles in 1970. He received his J.D. from the University of San Diego School of Law in 1973. In 1973, Mr. Hooper began his legal career with the California Department of Justice, where, as a Deputy Attorney General, he represented various state agencies in civil litigation involving health, education, and welfare matters. Since 1976, he has specialized in litigation against the federal and state governments involving health care matters. He has been involved in hundreds of administrative and judicial proceedings throughout the country as the lead trial and appellate attorney. His cases include some of the most important and complex Medicare, Medicaid and CHAMPUS cases in the health care field.
In 1987, Mr. Hooper, together with Bob Lundy and Lloyd Bookman, formed the national health care law firm of Hooper, Lundy & Bookman, P.C. in Los Angeles. As a founding member of Hooper, Lundy & Bookman, Mr. Hooper has continued to represent health care providers in health care disputes with federal and state governments throughout the country. In addition to his involvement in resolving disputes, Mr. Hooper also regularly advises nonprofit and for-profit health care organizations regarding reimbursement, certification, and licensure issues associated with business transactions and combinations. He continuously advises health care providers of Medicare, Medicaid, and CHAMPUS fraud and abuse issues and on state antirebate and referral issues.
Mr. Hooper is a former general counsel to the National Association of Psychiatric Treatment Centers for Children, and is a member of the American Health Lawyers Association, the Healthcare Financial Management Association, the California Society of Healthcare Attorneys, and the California Clinical Laboratory Association. He was also the first chair of the Fraud and Abuse Interest Group of the ABA Health Law Section.
Gary Marchant, Ph.D., J.D.,
Regents’ Professor and Lincoln Professor Emerging Technologies, Law and Ethics; Faculty Director, Center for Law, Science and Innovation, Sandra Day O’Connor College of Law, Arizona State University
Gary Marchant is Regent’s Professor and the Lincoln Professor Emerging Technologies, Law, and Ethics at the Sandra Day O’Connor College of Law at Arizona State University. He is also Faculty Director of the ASU Center for Law, Science and Innovation, Professor of Life Sciences, and a Senior Sustainability Scientist in the Global institute of Sustainability at ASU. Professor Marchant has a Ph.D. in Genetics from the University of British Columbia, a Masters of Public Policy degree from the Kennedy School of Government, and a JD from Harvard Law School.
Prior to joining the ASU faculty in 1999, he was a partner in the Washington, D.C. office of the law firm Kirkland & Ellis, where his practice focused on regulatory issues. Professor Marchant teaches and researches in the subject areas of environmental law, risk assessment and risk management, genetics and the law, biotechnology law, food and drug law, legal aspects of nanotechnology, and law, science, and technology.
Director, Business Intelligence, Boston Heart Diagnostics
Theo McCormick has over 25 years of health care experience in diagnostics, pharmaceuticals, and biotechnology organizations. He is focused on product development, launch, and marketing strategies. He currently serves as Director of Business Intelligence at Boston Heart Diagnostics.
Prior to joining Boston Heart Diagnostics, he led the Pharmaceutical & Diagnostics “RxDx” group at Management Science Associates and before that was the Director of Marketing for Laboratory Corporation of America (LabCorp), where he directed the marketing efforts for multiple assays including cardiovascular, infectious disease, gastroenterology, and pharmacogenomic portfolios. Previously, he was the Marketing Manager at Quest Diagnostics, where he was responsible for the strategic planning and marketing of the infectious disease molecular diagnostic testing portfolio.
Prior to entering the laboratory industry, he was at Pfizer, where he served as product manager with marketing responsibilities for Viracept, a HIV protease inhibitor. Mr. McCormick has also held various sales and marketing positions at Biogen [BiogenIDEC] and GlaxoWellcome [GlaxoSmithKline/GSK].
Richard A. Montagna, Ph.D.,
Senior Vice President for Scientific Affairs, Rheonix, Inc.
Richard A. Montagna has over 30 years of leadership experience and has managed the commercialization of over 40 biotechnology products. He was President of Innovative Biotechnologies International, Inc. prior to its acquisition by Rheonix, Inc. in 2008 and now serves as Rheonix’s Senior Vice President for Corporate Business Development and Scientific Affairs. Previously, he was Director of Biological Operations of Associated Biomedic Systems and President of Cellular Products. He has published 40 scientific papers and holds a number of patents in the biosensor area. He also holds an Adjunct Professorship in the Department of Biological and Environmental Engineering at Cornell University.
Dr. Montagna earned a Ph.D. in molecular biology from the University of Buffalo and served post docs at NYU Medical Center as an NIH Fellow in Experimental Pathology and at the University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, in the area of chemical carcinogenesis. In 1988, he testified before President Reagan's Presidential AIDS commission, providing data in support of a recommendation that the U.S. initiate mandatory screening of its donated blood supply for the presence of antibodies to HTLV-1, a human retrovirus related to the AIDS virus.
Managing Director, G2 Intelligence
Stephanie Murg is the Managing Director of G2 Intelligence, responsible for the live events business line as well as thought leadership roles in G2’s market research and advisory services.
Prior to joining G2, she was a research associate at JPMorganChase, Harvard Business School, and the National Bureau of Economic Research. She also has several years of laboratory experience in molecular and behavioral neuroscience research, with a focus on neurodegenerative disease.
Murg co-authored peer-reviewed publications in the Journal of Neuroscience, Human Gene Therapy, and Neurobiology of Learning and Memory, and co-wrote a chapter in the most recent edition of the textbook Neuropsychology of Memory. She received a bachelor’s degree in neurobiology from Harvard.
Nathaniel H. Robin, M.D. (FABMG),
Professor, Department of Genetics, University of Alabama at Birmingham
Nathaniel H. Robin attended Albert Einstein College of Medicine in the Bronx, New York, where he also completed a residency in pediatrics. He then proceeded to do a fellowship in Genetics at The Children’s Hospital Philadelphia/University of Pennsylvania. His first faculty position was in the Department of Genetics at Case Western Reserve University School of Medicine in 1995. In 2003, Dr. Robin joined the newly created Department of Genetics at the University of Alabama at Birmingham, where he is Professor of Genetics, Pediatrics, and Surgery-Otolaryngology as well as director of the Medical Genetics residency program.
Dr. Robin is board certified in Clinical Genetics by the American Board of Medical Genetics. His clinical practice is primarily as a general medical geneticist, with expertise in pediatric genetics, syndrome identification and genetic counseling. His areas of focused interest include craniofacial disorders, and the genetics of deafness.
While maintaining an active clinical practice, Dr. Robin has authored a book (Medical Genetics: Its Application to Speech, Hearing, and Craniofacial Disorders), 15 book chapters, over a dozen invited editorials, and over 100 peer-review publications. His writings cover a wide range of topics in genetics and include descriptions and studies on a variety of genetic syndromes. He has published studies that have looked at genetics testing for deafness, and on ethical issues in genetic testing, including issues of confidentiality and duty to warn at risk relatives.
CEO, CodeMap LLC
Dr. Charles Root is CEO of CodeMap, LLC. He has provided laboratory coding and reimbursement information to healthcare providers and manufacturers for over 22 years regarding compliance, coding and economic issues.
CodeMap’s clients include more than 50 diagnostic test manufacturers and over 1,500 health care providers (hospitals, independent laboratories and imaging centers) who rely on CodeMap publications, compliance training, and advisory services.
Publications by Dr. Root include: the CodeMap® Medicare Reimbursement Manual for Laboratory and Pathology, the CodeMap® Medicare Reimbursement Manual for Radiology and Nuclear Medicine, and the CodeMap® ICD-10-CM (Diagnosis) Reference Manual.
Dr. Root received his Ph.D. in physical chemistry and nuclear physics from the Catholic University of America, Washington, D.C., and has taken postgraduate courses in business management and economics from Harvard and Northwestern Universities. His experience includes market research, product development, and studies on the economic impact of government regulations on healthcare delivery costs.
Kevin P. Rosenblatt, M.D., Ph.D.,
Laboratory Director, Chief Medical and Scientific Officer, Companion Dx Reference Lab, LLC
Kevin Rosenblatt, Chairman, Chief Medical Officer, Chief Scientific Officer, Laboratory Director, and founder of Companion Dx Reference Laboratories, is a molecular pathologist who is recognized for this work in developing biomarkers (proteomics and genomics markers) for the diagnosis, prognosis, and therapeutics of various diseases, including cancer and neurodegenerative disease.
Dr. Rosenblatt is currently Associate Professor of Molecular Medicine and Director of the Center for Clinical Proteomics in The Centers for Proteomics and Systems Biology at the Brown Foundation Institute of Molecular Medicine. He is also Associate Professor of Pathology and Laboratory Medicine and Co-Director of the Proteomics Core for the Center for Clinical and Translational Sciences at UTHealth.
He attended Tulane University as an undergraduate where he majored in chemistry and religious studies. He then attended the University of Texas Southwestern Medical School at Dallas where he was a Perot Fellow in the Medical Scientist Training Program, an M.D.-Ph.D. degree program dedicated to developing academic physicians trained in basic science and clinical medicine.
He finished his graduate studies at Rockefeller University in Manhattan in the laboratory of Dr. A.J. Hudspeth, a pioneering neuroscientist and National Academy of Sciences member.
Product Manager, Sunquest Information Systems
Megan Schmidt is the Product Manager for Clinical Pathology Solutions at Sunquest Information Systems, Inc. Since joining Sunquest in 2010, Megan has been engaged in defining product strategy and development roadmap for the laboratory suite of products.
Before joining Sunquest, Megan acquired experience in product management at the division of Molecular Imaging at Carestream Health, Inc of Rochester, New York. Prior to that, Megan served as Business Manager of Qualification Services at PerkinElmer, Inc of Waltham, Massachusetts.
A graduate of The Catholic University of America in Washington, DC, Megan holds a Bachelor of Science Degree in Biology and is a certified Six Sigma Green Belt.
Nancy B. Spinner, Ph.D., FACMG,
Evelyn Willing Bromley Endowed Chair in Pathology, The Children's Hospital of Philadelphia; Chief, Division of Genomic Medicine; Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
Nancy B. Spinner, Ph.D. is the Evelyn Willing Bromley Professor of Pediatric Pathology, Chief of the Division of Human Genetics at The Children’s Hospital of Philadelphia, and a Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at The University of Pennsylvania. She received her Ph.D. training at The University of California, Berkeley, and her Fellowship Training in Cytogenetics at The Children’s Hospital of Philadelphia. She was the director of the Cytogenomics Laboratory from 1991 until assuming her position as Division Chief.
Her research interests are in the identification of the genetic etiology of Pediatric Disease, and her laboratory has made contributions to understanding the genetics of Alagille syndrome, Biliary Atresia, and the Ring Chromosome 20 syndrome in particular. She serves on the Scientific Advisory Board of the Alagille Syndrome Alliance, and is on the editorial board of Human Mutation and PLoS Genetics. She has received multiple teaching awards at The University of Pennsylvania, and a Faculty Mentoring Award from the Children’s Hospital of Philadelphia.
Dietrich A. Stephan, Ph.D.,
Founder, President, and CEO, SV Bio
Dietrich Stephan, the founder, president and CEO of SV Bio, is a geneticist, entrepreneur and recognized leader in the field of personalized medicine. Prior to SV Bio, he was Executive Director of the Gene Partnership at Harvard Medical School and Children’s Hospital Boston, where he architected and capitalized a groundbreaking genomic medicine pediatric program, as well as a genomic cancer program at Fox Chase Cancer Center. Dr. Stephan brought next-generation genome sequencing (NGS) to these clinical settings, with associated clinical decision support and sustainable business processes.
In 2006, Dr. Stephan founded Navigenics, Inc., a pioneering consumer genomics company, and later served as the company’s Chief Science Officer. Prior to that, he served as part of the leadership team of the Translational Genomics Research Institute (TGen), building it into one of the largest free-standing research institutes in the world. His roles at the Institute were Chairman of the Neurogenomics Department, Professor within the Institute, and Deputy Director for Discovery Research of the Institute overall. Dr. Stephan also served as Chairman of the NIH Neuroscience Microarray Consortium for seven years.
Dr. Stephan has published over 140 articles in peer-reviewed scientific journals, and he is a member of the Scientific Advisory Boards of many companies. He is on the Board of Directors of several organizations, including the Personalized Medicine Coalition, and continues to found biotechnology companies, including Aueon, Amnestix, and DiaVacs. Among numerous honors and awards, Dr. Stephan has won the Bio-IT World Grand Prize for Discovery Research in 2005, and the "Most Influential in Bringing Genomics to the Clinic" award at the Consumer Genetic Conference in 2010. Dr. Stephan earned a B.Sc. in biology from Carnegie Mellon University and a Ph.D. in human genetics from the University of Pittsburgh Graduate School of Public Health, where he was a 2012 Legacy Laureate.
Gregory J. Tsongalis, Ph.D., HCLD, CC,
Professor of Pathology; Director, Molecular Pathology; and Co-Director, Translational Research Program, Department of Pathology, Dartmouth Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth
Gregory Tsongalis is certified as a high-complexity clinical laboratory director (ABB) and is currently Professor of Pathology, Director of Molecular Pathology, and Co-Director of the Translational Research Program in the Department of Pathology at Dartmouth Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth. He received his Ph.D. in Pathology from the University of Medicine and Dentistry of New Jersey and completed his postdoctoral training in Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill. His area of expertise is in clinical molecular diagnostic applications for genetic, hematologic, infectious, and neoplastic diseases. His research interests are in the pathogenesis of solid tumors, disease association of SNP genotyping and personalized medicine.
Dr. Tsongalis has authored/edited eight textbooks in the field of molecular pathology, published more than 130 peer reviewed manuscripts, and has been an invited speaker at both national and international meetings. He has been the recipient of numerous investigator/scientist awards. He has served on numerous committees of the AACC, ASIP, and AMP where he is a past President. He is on the editorial board of Archiv Pathol Lab Med, J Clin Virol, Exper Molec Pathol, American Journal of Translational Research, and the International Journal of Clinical and Experimental Pathology. He also serves on numerous corporate scientific advisory boards.
Natalie Whitfield, Ph.D.
Division Manager, Clinical and Molecular Microbiology, University of Arizona Medical Center
Natalie Whitfield is the Division Manager of Clinical and Molecular Microbiology at the University of Arizona Medical Center and Clinical Assistant Professor in the department of Pathology at the University of Arizona. Her clinical service consists of management of the Division of Clinical and Molecular Microbiology to support laboratory medicine objectives, which provides services to the University of Arizona Health Network clinics, hospital units, nursing homes, and other institutions. She performs technical and laboratory operational oversight of the following laboratory subspecialties in clinical microbiology: molecular diagnostics, bacteriology, virology, mycology, parasitology, serology, and antimicrobial susceptibility testing, as well as financial planning for the Division of Clinical Microbiology. The remainder of her service is through community service/work/lectures, and she is a member of local, state, national, international organizations, committees, societies, and/or boards, serving diagnostic microbiology.
Vice President of Commercialization Strategies, Consulting, and Industry Affairs, XIFIN
Ms. Wolf is a nationally recognized expert in the field of laboratory commercialization and reimbursement, with over 20 years of experience in the diagnostic laboratory industry, specializing in Molecular Diagnostic Laboratories. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S.
She is a former President and board member of the California Clinical Laboratory Association and is an active participant with the ACLA (American Clinical Laboratory Association) and the Personalized Medicine Coalition. Most recently Ms. Wolf held the position of Vice President of Reimbursement and Regulatory Affairs at Axial Biotech, Inc. where she was responsible for creating and implementing their successful reimbursement strategies. Prior to joining Axial Biotech, Inc., Ms. Wolf held executive positions in the area of commercialization and reimbursement at RedPath Integrated Pathology, Inc., Genomic Health, Inc., and Esoterix (now LabCorp).
Ms. Wolf has a Bachelor of Arts degree from UCLA and a Masters of HealthCare Administration.